Takeda reports positive Phase 2/3 trial results for TAK-881 in immune disorder

May 4, 2026 8:00 AM

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) announced that its investigational treatment TAK-881 met the primary endpoint in a pivotal Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found